Search Results

Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations MOA: Zongertinib is an oral, selective HER2 TKI Key Eligibility: Confirmed diagnosis of Stage II-IIIB (up to T4, max…

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study Of Mavorixafor In Participants With Congenital And Acquired Primary Autoimmune And Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent And/Or Serious Infections MOA: Mavorixafor is a CXCR4 antagonist that blocks the binding of the CXCR4 ligand, SDF 1α/CXC chemokine ligand 12. Key Eligibility: Diagnosis of congenital or…

A Phase II, Nonrandomized, Single-Arm Study of Elranatamab Outpatient Administration in Patients with Relapsed/Refractory Multiple Myeloma MOA; Elranatamab is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate malignant plasma cells in MM. Key Eligibility: Documented diagnosis of relapsed/refractory MM according to IMWG criteria Must have received ≥1 prior LOT…

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD-(L)1 therapy based on PD-L1 negative disease (ROSETTA Breast-01) MOA: BNT327 (pumitamig) is a bispecific antibody that targets PD-L1 and VEGF-A. Key Eligibility: Confirmed…

Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan Maintenance With or Without Bevacizumab vs Standard of Care in Participants With Newly Diagnosed Advanced HRD Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102) MOA: Sacituzumabtirumotecan (Sac-TMT) is a TROP2 targeting ADC with a TOP1i payload. Key Eligibility Confirmed FIGO Stage III or IV epithelial OC/FT/PPC…

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301) MOA: Atebimetinib (IMM-1 104) is a deep cyclic dual inhibitor of MEK1 and MEK2 Key Eligibility: Subjects’…